The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).
 
Yann-Alexandre Vano
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
 
Nathalie Rioux-Leclercq
No Relationships to Disclose
 
Cécile Dalban
No Relationships to Disclose
 
Catherine Sautes-Fridman
No Relationships to Disclose
 
Antoine Bougoüin
No Relationships to Disclose
 
Nathalie Chaput
No Relationships to Disclose
 
Salem Chouaib
No Relationships to Disclose
 
Benoit Beuselinck
No Relationships to Disclose
 
Christine Chevreau
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer/Ipsen
 
Marine Gross-Goupil
Consulting or Advisory Role - Amgen; Astellas Medivation; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); ipsen (Inst); Janssen-Cilag (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; ipsen; MSD Oncology; Roche; Roche; Roche
 
Sylvie Negrier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer
Research Funding - IPSEN (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA PHARMA; IPSEN; Novartis; Pfizer
 
Brigitte Laguerre
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen-Cilag; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; Novartis; pfizer
 
Delphine Borchiellini
No Relationships to Disclose
 
Irelka Colina-Moreno
No Relationships to Disclose
 
Wolf-Herman Fridman
No Relationships to Disclose
 
Sylvie Chabaud
No Relationships to Disclose
 
Florence Tantot
No Relationships to Disclose
 
Janice Barros Monteiro
No Relationships to Disclose
 
Bernard Escudier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Oncorena; Pfizer; Roche/Genentech
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche/Genentech
 
Laurence Albiges
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Peloton therapeutics (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD